ITOS vs. TSHA, NK, VXRT, TWST, VCEL, IMCR, ADMA, CGON, RXRX, and NVAX
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Taysha Gene Therapies (TSHA), NantKwest (NK), Vaxart (VXRT), Twist Bioscience (TWST), Vericel (VCEL), Immunocore (IMCR), ADMA Biologics (ADMA), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), and Novavax (NVAX). These companies are all part of the "medical" sector.
Taysha Gene Therapies (NASDAQ:TSHA) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
Taysha Gene Therapies currently has a consensus price target of $7.00, suggesting a potential upside of 115.38%. iTeos Therapeutics has a consensus price target of $31.00, suggesting a potential upside of 81.50%. Given iTeos Therapeutics' higher possible upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than iTeos Therapeutics.
Taysha Gene Therapies received 59 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. Likewise, 74.17% of users gave Taysha Gene Therapies an outperform vote while only 73.17% of users gave iTeos Therapeutics an outperform vote.
Taysha Gene Therapies has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
iTeos Therapeutics has a net margin of 0.00% compared to iTeos Therapeutics' net margin of -833.60%. Taysha Gene Therapies' return on equity of -23.15% beat iTeos Therapeutics' return on equity.
In the previous week, Taysha Gene Therapies had 4 more articles in the media than iTeos Therapeutics. MarketBeat recorded 6 mentions for Taysha Gene Therapies and 2 mentions for iTeos Therapeutics. Taysha Gene Therapies' average media sentiment score of 1.81 beat iTeos Therapeutics' score of 1.25 indicating that iTeos Therapeutics is being referred to more favorably in the news media.
77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 2.7% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Taysha Gene Therapies has higher revenue and earnings than iTeos Therapeutics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
iTeos Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
